Kestra Medical Technologies (NASDAQ:KMTS) CFO Sells $146,512.80 in Stock

Key Points

• CFO Vaseem Mahboob sold 4,788 KMTS shares at an average price of $30.60, generating $146,512.80 and reducing his holdings by 7.32% to 60,609 shares.
• Kestra shares traded near their 12-month high at $30.61, with a $1.82 billion market capitalization, but the company remains unprofitable after missing quarterly EPS estimates and reporting a negative net margin.
• Analyst sentiment remains a “Moderate Buy”, supported by five Buy ratings, two Holds, and one Sell, though the $29 consensus price target is below the current share price.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) CFO Vaseem Mahboob sold 4,788 shares of the business's stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $30.60, for a total value of $146,512.80. Following the completion of the transaction, the chief financial officer owned 60,609 shares in the company, valued at $1,854,635.40. This trade represents a 7.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Vaseem Mahboob also recently made the following trade(s):

• On Tuesday, October 27th, Vaseem Mahboob sold 34,809 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.04, for a total value of $1,045,662.36.
• On Wednesday, October 28th, Vaseem Mahboob sold 39,903 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.48, for a total value of $1,216,243.44.
• On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.88, for a total transaction of $680,307.56.
• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.68, for a total transaction of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total value of $199,352.37.

Kestra Medical Technologies Price Performance

Shares of Kestra Medical Technologies stock traded up $0.74 during trading on Thursday, reaching $30.61. The company's stock had a trading volume of 470,598 shares, compared to its average volume of 351,886. The business has a 50 day moving average price of $26.59 and a 200-day moving average price of $23.76. Kestra Medical Technologies, Ltd. has a 12-month low of $17.34 and a 12-month high of $31.04. The company has a market capitalization of $1.82 billion, a P/E ratio of -11.46 and a beta of 0.51. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million during the quarter. As a group, sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on KMTS. JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a report on Monday, August 10th. They set an "overweight" rating and a $30.00 price objective for the company. BTIG Research reaffirmed a "buy" rating and set a $32.00 price target on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Weiss Ratings raised shares of Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, September 16th. Piper Sandler restated an "overweight" rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, Royal Bank Of Canada set a $30.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $29.00.

Institutional Investors Weigh In On Kestra Medical Technologies

Hedge funds have recently modified their holdings of the company. Corient Private Wealth LP lifted its stake in shares of Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company's stock worth $1,542,000 after purchasing an additional 44,839 shares during the period. Sei Investments Co. boosted its holdings in Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company's stock valued at $4,726,000 after acquiring an additional 43,753 shares during the last quarter. Spartan Wealth Advisory Services LLC purchased a new stake in Kestra Medical Technologies during the first quarter valued at about $603,000. Quantinno Capital Management LP acquired a new stake in Kestra Medical Technologies during the first quarter worth about $431,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company's stock worth $1,397,000 after purchasing an additional 22,471 shares during the period.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.